DYN Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $34.0M.
Where they traded
Last open-market purchase: June 8, 2026 , by Posner Brian S .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Cox John | CEO & President | Sell 10b5-1 | 5,658 | $18.88 | $106.8K | 357,507 −1.6% of holding | |
| Kerr Douglas | Chief Medical Officer | Sell 10b5-1 | 1,290 | $18.88 | $24.4K | 162,564 −0.8% of holding | |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sell 10b5-1 | 185 | $18.88 | $3.5K | 152,897 −0.1% of holding | |
| Kerr Douglas | Chief Medical Officer | Sell 10b5-1 | 3,745 | $24.35 | $91.2K | 163,854 −2.2% of holding | |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sell 10b5-1 | 900 | $24.35 | $21.9K | 153,082 −0.6% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 2,160,516 | $25.00 | $54.0M | 2,441,454 −46.9% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 426,412 | $26.20 | $11.2M | 3,801,128 −10.1% of holding | |
| Cox John | CEO & President | Sell 10b5-1 | 4,986 | $26.28 | $131.0K | 363,165 −1.4% of holding | |
| Lucera Erick | Chief Financial Officer | Sell 10b5-1 | 1,797 | $26.28 | $47.2K | 119,766 −1.5% of holding | |
| Kerr Douglas | Chief Medical Officer | Sell 10b5-1 | 1,556 | $26.28 | $40.9K | 167,599 −0.9% of holding | |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sell 10b5-1 | 226 | $26.28 | $5.9K | 153,982 −0.1% of holding | |
| Kersten Dirk 2 fills | Director | Sell 10b5-1 | 261,460 | $25.51 | $6.7M | 3,592,184 −6.8% of holding | |
| Rhodes Jason P 6 fills | Director | Sell 10b5-1 | 292,211 | $23.26 | $6.8M | 4,099,069 −6.7% of holding | |
| Rhodes Jason P | Director | Sell | 5,000 | $23.61 | $118.1K | 2,962 −62.8% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 480,240 | $22.79 | $10.9M | 4,223,448 −10.2% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 195,427 | $21.14 | $4.1M | 4,476,487 −4.2% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 309,268 | $21.28 | $6.6M | 4,579,456 −6.3% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 24,100 | $21.10 | $508.5K | 4,742,410 −0.5% of holding | |
| Lucera Erick | Chief Financial Officer | Sell | 2,362 | $20.37 | $48.1K | 121,563 −1.9% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 95,900 | $21.02 | $2.0M | 4,755,109 −2% of holding | |
| Rhodes Jason P 3 fills | Director | Sell 10b5-1 | 147,760 | $21.13 | $3.1M | 4,805,639 −3% of holding | |
| Kersten Dirk 2 fills | Director | Sell 10b5-1 | 73,286 | $21.05 | $1.5M | 3,849,913 −1.9% of holding | |
| Kersten Dirk | Director | Sell 10b5-1 | 190,676 | $20.57 | $3.9M | 3,921,542 −4.6% of holding | |
| Kersten Dirk | Director | Sell 10b5-1 | 46,901 | $20.07 | $941.4K | 4,112,218 −1.1% of holding | |
| Kersten Dirk | Director | Sell 10b5-1 | 37,454 | $20.14 | $754.3K | 4,159,119 −0.9% of holding | |
| Cox John | CEO & President | Sell 10b5-1 | 2,683 | $18.33 | $49.2K | 368,151 −0.7% of holding | |
| Kerr Douglas | Chief Medical Officer | Sell 10b5-1 | 887 | $18.33 | $16.3K | 169,155 −0.5% of holding | |
| Friedl-Naderer Johanna | Chief Commercial Officer | Sell 10b5-1 | 145 | $18.33 | $2.7K | 154,208 −0.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.